- Home
- KNDI vs TLSA Comparison
KNDI vs TLSA Comparison
Compare KNDI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- TLSA
- Stock Information
- Founded
- KNDI 2002
- TLSA 2013
- Country
- KNDI China
- TLSA United Kingdom
- Employees
- KNDI N/A
- TLSA N/A
- Industry
- KNDI Auto Manufacturing
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- TLSA Health Care
- Exchange
- KNDI Nasdaq
- TLSA Nasdaq
- Market Cap
- KNDI 96.3M
- TLSA 187.0M
- IPO Year
- KNDI N/A
- TLSA 2000
- Fundamental
- Price
- KNDI $1.20
- TLSA $1.45
- Analyst Decision
- KNDI
- TLSA
- Analyst Count
- KNDI 0
- TLSA 0
- Target Price
- KNDI N/A
- TLSA N/A
- AVG Volume (30 Days)
- KNDI 109.2K
- TLSA 247.0K
- Earning Date
- KNDI 08-15-2025
- TLSA 07-22-2025
- Dividend Yield
- KNDI N/A
- TLSA N/A
- EPS Growth
- KNDI N/A
- TLSA N/A
- EPS
- KNDI N/A
- TLSA N/A
- Revenue
- KNDI $127,569,613.00
- TLSA N/A
- Revenue This Year
- KNDI N/A
- TLSA N/A
- Revenue Next Year
- KNDI N/A
- TLSA N/A
- P/E Ratio
- KNDI N/A
- TLSA N/A
- Revenue Growth
- KNDI 3.21
- TLSA N/A
- 52 Week Low
- KNDI $0.89
- TLSA $0.63
- 52 Week High
- KNDI $2.07
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- KNDI 52.54
- TLSA 48.43
- Support Level
- KNDI $1.09
- TLSA $1.43
- Resistance Level
- KNDI $1.17
- TLSA $1.81
- Average True Range (ATR)
- KNDI 0.07
- TLSA 0.09
- MACD
- KNDI 0.01
- TLSA -0.02
- Stochastic Oscillator
- KNDI 61.23
- TLSA 18.53
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.